title: Evidence for nonacetylcholinesterase targets of organophosphorus nerve agent: supersensitivity of acetylcholinesterase knockout mouse to VX lethality.
abstract: The possibility that organophosphate toxicity is due to inhibition of targets other than acetylcholinesterase (AChE, EC 3.1.1.7) was examined in AChE knockout mice. Mice (34-55 days old) were grouped for this study, after it was determined that AChE, butyrylcholinesterase (BChE), and carboxylesterase activities had reached stable values by this age. Mice with 0, 50, or 100% AChE activity were treated subcutaneously with the nerve agent VX. The LD50 for VX was 10 to 12 microg/kg in AChE-/-, 17 microg/kg in AChE+/-, and 24 microg/kg in AChE+/+ mice. The same cholinergic signs of toxicity were present in AChE-/- mice as in wild-type mice, even though AChE-/- mice have no AChE whose inhibition could lead to cholinergic signs. Wild-type mice, but not AChE-/- mice, were protected by pretreatment with atropine. Tissues were extracted from VX-treated and untreated animals and tested for AChE, BChE, and acylpeptide hydrolase activity. VX treatment inhibited 50% of the AChE activity in brain and muscle of AChE+/+ and +/- mice, 50% of the BChE activity in all three AChE genotypes, but did not significantly inhibit acylpeptide hydrolase activity. It was concluded that the toxicity of VX must be attributed to inhibition of nonacetylcholinesterase targets in the AChE-/- mouse. Organophosphorus ester toxicity in wild-type mice is probably due to inhibition or binding to several proteins, only one of which is AChE.
authors.affiliation: Eppley Institute, University of Nebraska Medical Center, Omaha, Nebraska 68198-6805, USA.
authors.forename: E G
authors.initials: EG
authors.lastname: Duysen
authors.forename: B
authors.initials: B
authors.lastname: Li
authors.forename: W
authors.initials: W
authors.lastname: Xie
authors.forename: L M
authors.initials: LM
authors.lastname: Schopfer
authors.forename: R S
authors.initials: RS
authors.lastname: Anderson
authors.forename: C A
authors.initials: CA
authors.lastname: Broomfield
authors.forename: O
authors.initials: O
authors.lastname: Lockridge
mesh_terms: D000110:Acetylcholinesterase / Q000235:genetics / Q000378:metabolism / Q000502:physiology*; D000375:Aging / Q000502:physiology; D000818:Animals; D001285:Atropine / Q000494:pharmacology; D001522:Behavior, Animal / Q000187:drug effects; D001831:Body Temperature / Q000187:drug effects; D002619:Chemical Warfare Agents / Q000493:pharmacokinetics / Q000633:toxicity*; D002800:Cholinesterase Inhibitors / Q000493:pharmacokinetics / Q000633:toxicity*; D002802:Cholinesterases / Q000378:metabolism; D006197:Hair / Q000473:pathology; D018737:Hand Strength; D007928:Lethal Dose 50; D051379:Mice; D018345:Mice, Knockout; D009043:Motor Activity / Q000187:drug effects; D018727:Muscarinic Antagonists / Q000494:pharmacology; D009946:Organothiophosphorus Compounds / Q000633:toxicity*; D014018:Tissue Distribution; D014202:Tremor / Q000139:chemically induced; D014664:Vasodilation / Q000187:drug effects
chemical_list: D000110:Acetylcholinesterase; D001285:Atropine; D002619:Chemical Warfare Agents; D002800:Cholinesterase Inhibitors; D002802:Cholinesterases; D018727:Muscarinic Antagonists; D009946:Organothiophosphorus Compounds; C009680:VX-agent